Which sequencing technology does Precise Tumor use to analyze genetic material?

• A. Next-generation sequencing (NGS) of DNA and RNA
• B. Sanger sequencing
• C. Microarray analysis
• D. Quantitative PCR

Answer: (A)

Next-generation sequencing of DNA and RNA is the approach that provides the most comprehensive view of a tumor’s genetic material. By sequencing both the genome and the transcriptome, this method detects a wide range of alterations: DNA-level changes such as point mutations, insertions and deletions, copy number variations, and structural rearrangements, plus RNA-level information like gene expression differences and fusion transcripts. The combination of breadth and depth lets a single test profile actionable mutations, expression patterns, and potential fusions that guide targeted therapies and clinical decisions.

Sanger sequencing, while highly accurate for small regions, is not practical for broad tumor profiling because it sequences only one fragment at a time, making it slow and limited in scope. Microarray analysis can assess expression levels or copy-number changes but does not provide base-by-base sequence data and cannot readily identify novel variants. Quantitative PCR is fast and sensitive but is restricted to predefined targets and cannot comprehensively survey the genome or transcriptome.

So, using next-generation sequencing of DNA and RNA offers the most versatile and informative analysis for Precise Tumor’s genetic material.